Nicox Announces First Commercial Sale of Zerviate in China by Partner Ocumension

Nicox announced the first commercial sale of Zerviate (cetirizine ophthalmic solution), 0.24% in China by its exclusive Chinese partner Ocumension yesterday – a significant milestone in their longstanding collaboration since 2018. 

Zerviate is indicated for ocular itching associated with allergic conjunctivitis and was approved in China in September 2024. It is the first eye drop formulation of the antihistamine cetirizine, and it is currently commercialized in the United States by Nicox’s exclusive U.S. partner, Harrow, Inc. Zerviate is safe to treat allergic conjunctivitis in both toddlers and preschoolers, addressing a large gap in pediatric eye care in China. 

“Ocumension has proven itself to be a strong development partner through their work on Zerviate and on the recruitment of Chinese patients in the NCX 470 Denali Phase 3 study. We look forward to continuing to work with them as we advance NCX 470 towards commercialization as well,” Gavin Spencer, Chief Executive Officer of Nicox, said in a recent company press release. 

The France-based company also announced that the commercialization of Zerviate will provide an import new revenue stream for Nicox up to $17 million USD. Zerviate is exclusively licensed to Ocumension for development and commercialization in the Chinese and the majority of the Southeast Asian markets.